Abstract
Background/Aims: Connective tissue growth factor (CTGF; CCN2) has been implicated as a marker and mediator of fibrosis in human and experimental renal disease. Methods: We performed a comparative analysis of CTGF expression in hypertensive patients with and without nephrosclerosis, and in uninephrectomized and sham-operated spontaneously hypertensive rats (UNX-SHR and 2K-SHR). Results: Urinary and plasma CTGF were elevated in patients with hypertensive nephrosclerosis, and increased renal CTGF expression was mainly localized in podocytes. Accordingly, elevation of urinary, plasma, and tissue CTGF in UNX-SHR coincided and correlated with proteinuria, glomerulosclerosis, and tubulointerstitial fibrosis. Thirty-two weeks after uninephrectomy, mean glomerular CTGF mRNA expression was increased 1.3-fold over baseline, mainly due to 1.7-fold higher expression in glomeruli undergoing sclerosis. In parallel, tubulointerstitial CTGF and α-smooth muscle actin were upregulated in UNX-SHR. CTGF was increased in the media of arcuate and interlobar arteries, while arterioles remained negative. Conclusions: Glomerulosclerosis, tubulointerstitial fibrosis, and arterial media hypertrophy lesions of hypertensive nephrosclerosis are all characterized by increased CTGF tissue expression, which is associated with a concomitant increase in CTGF in blood and urine. These findings identify CTGF as a promising biomarker for progression of hypertensive nephrosclerosis, and as a likely key factor in the pathogenesis of this disease.
Journal Section:
Original Paper
References
1.
Barri YM: Hypertension and kidney disease: a deadly connection. Curr Hypertens Rep 2008;10:39–45.
[PubMed]
2.
Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, Ross R: Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 1992;175:1413–1416.
[PubMed]
3.
Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350–1358.
[PubMed]
4.
Gupta S, Clarkson MR, Duggan J, Brady HR: Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000;58:1389–1399.
[PubMed]
5.
Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR: Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999;274:5830–5834.
[PubMed]
6.
Igarashi A, Okochi H, Bradham DM, Grotendorst GR: Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 1993;4:637–645.
[PubMed]
7.
Kanemoto K, Usui J, Tomari S, Yokoi H, Mukoyama M, Aten J, Weening JJ, Nagata M: Connective tissue growth factor participates in scar formation of crescentic glomerulonephritis. Lab Invest 2003;83:1615–1625.
[PubMed]
8.
Weston BS, Wahab NA, Mason RM: CTGF mediates TGF-beta-induced fibronectin matrix deposition by upregulating active alpha5beta1 integrin in human mesangial cells. J Am Soc Nephrol 2003;14:601–610.
[PubMed]
9.
Nguyen TQ, Goldschmeding R: Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis? Pharm Res 2008;25:2416–2426.
[PubMed]
10.
Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R: Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998;53:853–861.
[PubMed]
11.
de las Heras N, Ruiz-Ortega M, Ruperez M, Sanz-Rosa D, Miana M, Aragoncillo P, Mezzano S, Lahera V, Egido J, Cachofeiro V: Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin II. J Renin Angiotensin Aldosterone Syst 2006;7:192–200.
[PubMed]
12.
de las Heras N, Ruiz-Ortega M, Miana M, Ruperez M, Sanz-Rosa D, Aragoncillo P, Mezzano S, Cachofeiro V, Egido J, Lahera V: Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. J Hypertens 2007;25:629–638.
[PubMed]
13.
Dworkin LD, Feiner HD: Glomerular injury in uninephrectomized spontaneously hypertensive rats. A consequence of glomerular capillary hypertension. J Clin Invest 1986;77:797–809.
[PubMed]
14.
Geiger H, Fierlbeck W, Mai M, Ruchti H, Schonfeld V, Dammrich J, Hugo C, Neumayer HH: Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR. Kidney Int 1997;51:750–761.
[PubMed]
15.
Vassalotti JA, Stevens LA, Levey AS: Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007;50:169–180.
[PubMed]
16.
Roestenberg P, van Nieuwenhoven FA, Wieten L, Boer P, Diekman T, Tiller AM, Wiersinga WM, Oliver N, Usinger W, Weitz S, Schlingemann RO, Goldschmeding R: Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 2004;27:1164–1170.
[PubMed]
17.
Nguyen TQ, Tarnow L, Andersen S, Hovind P, Parving HH, Goldschmeding R, van Nieuwenhoven FA: Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006;29:83–88.
[PubMed]
18.
Roestenberg P, van Nieuwenhoven FA, Joles JA, Trischberger C, Martens PP, Oliver N, Aten J, Hoppener JW, Goldschmeding R: Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Renal Physiol 2006;290:F1344–F1354.
[PubMed]
19.
Nguyen TQ, Roestenberg P, van Nieuwenhoven FA, Bovenschen N, Li Z, Xu L, Oliver N, Aten J, Joles JA, Vial C, Brandan E, Lyons KM, Goldschmeding R: CTGF inhibits BMP-7 signaling in diabetic nephropathy. J Am Soc Nephrol 2008;19:2098–2107.
[PubMed]
20.
Ito Y, Goldschmeding R, Bende R, Claessen N, Chand M, Kleij L, Rabelink T, Weening J, Aten J: Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J Am Soc Nephrol 2001;12:472–484.
[PubMed]
21.
Turk T, Leeuwis JW, Gray J, Torti SV, Lyons KM, Nguyen TQ, Goldschmeding R: BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J Histochem Cytochem 2009;57:623–631.
[PubMed]
22.
Ott C, Iwanciw D, Graness A, Giehl K, Goppelt-Struebe M: Modulation of the expression of connective tissue growth factor by alterations of the cytoskeleton. J Biol Chem 2003;278:44305–44311.
[PubMed]
23.
Oba S, Kimura K, Suzuki N, Mise N, Tojo A, Miyashita K, Konno Y, Hirata Y, Goto A, Omata M: Relevance of periglomerular myofibroblasts in progression of human glomerulonephritis. Am J Kidney Dis 1998;32:419–425.
[PubMed]
24.
Risdon RA, Sloper JC, De Wardener HE: Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968;ii:363–366.
[PubMed]
25.
Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996;7:2495–2508.
[PubMed]
26.
Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG: Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002;110:341–350.
[PubMed]
27.
Liu BC, Zhang JD, Zhang XL, Wu GQ, Li MX: Role of connective tissue growth factor (CTGF) module 4 in regulating epithelial mesenchymal transition (EMT) in HK-2 cells. Clin Chim Acta 2006;373:144–150.
[PubMed]
28.
Shi Y, Tu Z, Wang W, Li Q, Ye F, Wang J, Qiu J, Zhang L, Bu H, Li Y: Homologous peptide of connective tissue growth factor ameliorates epithelial to mesenchymal transition of tubular epithelial cells. Cytokine 2006;36:35–44.
[PubMed]
29.
Owens GK: Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 1987;9:178–187.
[PubMed]
30.
Owens GK, Schwartz SM: Alterations in vascular smooth muscle mass in the spontaneously hypertensive rat. Role of cellular hypertrophy, hyperploidy, and hyperplasia. Circ Res 1982;51:280–289.
[PubMed]
31.
Korsgaard N, Aalkjaer C, Heagerty AM, Izzard AS, Mulvany MJ: Histology of subcutaneous small arteries from patients with essential hypertension. Hypertension 1993;22:523–526.
[PubMed]
© 2010 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2010
You do not currently have access to this content.
